weight loss glp-1 agonists GLP-1s for Loss: What You Need to Know The Landscape Of GLP-1 Receptor

Ouyang, Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents, Int

HR 1.19, 95% CI 0.91.58), but not for the other DPP-4 inhibitors as in the TECOS study for sitagliptin (HR 1.00, 95% CI 0.831.20) or the CARMELINA study for linagliptin (HR 0.90, 95% CI 0.741.08) (57, 62, 64, 65, 68)

Prescription Type 17.13.5

Meanwhile, other GLP-1 agonists, such as Ozempic, are actually meant for the treatment of type 2 diabetes

A 2025 Stanford University interview with psychiatrist Anna Lembke touches on positive connections between the dopamine-stabilizing effects of GLP-1 medications on food addictions and the similar needs of patients with other drug addiction issues

The large number of paragraph IV certifications on GLP-1 receptor agonists and the short median duration of time from brand-name approval to first paragraph IV certification (6.8 years) suggests that the barriers to generic GLP-1 receptor agonist entry may differ in important ways from the barriers for other drug-device combinations such as inhalers